STOCK TITAN
  1. Home
  2. News
  3. IKT

Inhibikase Therapeutics, Inc. - IKT STOCK NEWS

Welcome to our dedicated news page for Inhibikase Therapeutics (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inhibikase Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inhibikase Therapeutics 's position in the market.

News
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported financial results for Q3 2023 and highlighted recent developments, including advancements in the Phase 2 '201' Trial of Risvodetinib in untreated Parkinson’s disease, Orphan Drug Designation for MSA treatment, completion of bioequivalence studies with IkT-001Pro, and initiation of preclinical development of second-generation c-Abl inhibitors. The company also disclosed Q3 financial results, with a net loss of $4.60 million and a cash position of $16.83 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
earnings
-
News
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will report financial results for the third quarter ended September 30, 2023, on November 14, 2023, after the close of U.S. markets. The Company will host a conference call and webcast on November 15, 2023, to provide a corporate update and review the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
conferences earnings
-
News
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
Rhea-AI Summary
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will report financial results for Q3 2023 on November 14, 2023, and host a conference call on November 15, 2023, to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
conferences earnings
News
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
Rhea-AI Summary
Inhibikase Therapeutics' risvodetinib granted Orphan Drug Designation for the treatment of Multiple System Atrophy (MSA), a form of Parkinsonism, by the FDA. The designation highlights the high unmet medical need in this patient population. Risvodetinib has the potential to slow or halt disease progression. The company plans to conduct Phase 2 clinical studies and believes success in MSA could lead to potential success in other forms of Parkinsonism. Orphan Drug Designation provides certain incentives and regulatory assistance to sponsors, including tax credits and potential marketing exclusivity upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.43%
Tags
clinical trial
-
News
Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
Rhea-AI Summary
Inhibikase Therapeutics develops tablet formulation of risvodetinib to improve drug exposure and patient use
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
News
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
Rhea-AI Summary
Inhibikase Therapeutics to present at International Congress of Parkinson's Disease and Movement Disorders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.33%
Tags
conferences
News
Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
Rhea-AI Summary
Inhibikase Therapeutics is assessing new molecules for c-Abl inhibition and has named IkT-148009 as risvodetinib ('risvo').
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
none
-
News
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
Rhea-AI Summary
Inhibikase completes bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate, plans to discuss regulatory approval pathway with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
none
-
News
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
earnings
News
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
conferences earnings
Stock IKT logo
Inhibikase Therapeutics, Inc.

Nasdaq:IKT

IKT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IKT Stock Data

8.74M
5.57M
13.85%
9.58%
0.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ATLANTA

About IKT

inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.